Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (49)6%
With exclusions (46)8%
Mortality (47)4%
Recovery (10)14%
Viral clearance (2)−7%
RCTs (13)13%
RCT mortality (12)13%
Late (49)6%
00.511.5+
← Tocilizumab
reduces riskIncreased
risk →
reduces riskIncreased
risk →
